ClinicalTrials.gg
CompletedNCT05247918OBDIPHYUpdated Mar 17, 2026

OBDIPHY (OBesity DIgital-PHYsical Care Study)

An interventional study of Digital-physical care and Treatment as usual in Pediatric Obesity, Obesity and Adolescent Obesity, sponsored by Göteborg University. Completed at 5 sites in Sweden. Open to participants aged 10 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Göteborg University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
10 Years to 16 Years
Sex
All
01

Study summary

This is a prospective randomized controlled multicentre non-inferiority trial. The aim of this study to evaluate digi-physical care compared to regular physical/in person care and investigate if digi-physical care can be an equal or even better treatment alternative among families with children or adolescents living with obesity in Sweden. The study participants will either get treatment as usual or treatment as usual combined with digi-physical solution. The digi-physical solution includes thar half of the session is digital and they get an app where they can self-monitoring health data, have an overview over they treatment plan and easy communicate with theirs caregivers.

Read the detailed description

This study is multi centre in three different county council in southwest of Sweden which include children and adolescents in the age of 10-16 year. The study participants will either get treatment as usual, which includes four in person session with healthcare professionals as doctor, nurse or dietitian (the control group) or treatment as usual combined with digi-physical solution (intervention group). The intervention group will beyond treatment as usual get a digital communication platform (including an app) where the patient has a good overview of their treatment plan, can report self-monitored health data as daily steps and weight once a week and monitor the daily work with their selected health goal. Everything in the app is individually tailored together with the patient. The patient with digi-physical care will also have assess to a chat for communication with their caregivers. The app has a high degree of authentication and classified as a journal system. Half of yearly treatment as usual sessions will be digital for the intervention group.

The digi-physical method of treatment is developed and based on the desire from the patient association HOBS (hälsa oberoende av storlek). In parts of Sweden people have long distance to the clinic which makes it difficult to be present at the treatment in-clinic sessions and the families loses many hours away from school and work. The null hypothesis is that digi-physical care will have a positive effect on BMI SDS, however inferior to treatment as usual.

In addition to evaluate that this new treatment alternative is safe will also ISO-BMI, weight development and metabolic risk factors be evaluated. The study does not include any extra blood samples or visits to the clinic thus everything is collected according to regular care programs. To evaluate the food intake and possible changes there will be three 24-h recalls, combined with riksmaten flex, performed. There will also be questions about their physical activity and a survey (PEDS-QL) for mental health. For a few volunteered patient families, approximate 15-20, will participate in semi-structured deep interviews.

02

Conditions studied

  • Pediatric Obesity
  • Obesity
  • Adolescent Obesity
  • Lifestyle Risk Reduction
  • Metabolic Syndrome
  • Weight Loss
03

In context

Pediatric Obesity

1,129 studies on the registry are indexed under Pediatric Obesity; 187 are open to participants now.

This study's enrollment of 102 is close to the median of 100 across 870 interventional studies indexed under Pediatric Obesity.

Browse Pediatric Obesity studies →

Lead sponsor

Göteborg University is the lead sponsor of 270 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ISO- 30 or above.

Exclusion criteria

Exclusion Criteria:

  • Lack of Swedish skills
  • Patients potential for obesity surgery
  • Patient with obesity syndrome
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Digital-physical care group

    Combination of digital and physical care.

    Behavioral: Digital-physical care

  • Active comparator
    Treatment as usual.

    Treatment as usual in accordance with national guidelines.

    Behavioral: Treatment as usual

Interventions

  • BehavioralDigital-physical care

    Patients will get access to a digital communication platform. Two in person session and two digital contacts per year with possibility to chat with caregivers in between.

  • BehavioralTreatment as usual

    Four in person session at the center in a year.

06

What researchers measure

Primary outcomes

  1. Change from baseline in BMI standard deviation score at month 12.

    The BMI standard-deviation score is a measure of the number of standard deviations from the population mean BMI (weight divided by height squared), matched for age and sex.

    Time frame: Baseline and month 12.

Secondary outcomes

  1. Change from baseline in BMI standard deviation score at month 6.

    The BMI standard-deviation score is a measure of the number of standard deviations from the population mean BMI (weight divided by height squared), matched for age and sex.

    Time frame: Baseline and month 6.

  2. Change from baseline in BMI standard deviation score at month 18.

    The BMI standard-deviation score is a measure of the number of standard deviations from the population mean BMI (weight divided by height squared), matched for age and sex.

    Time frame: Baseline and month 18

  3. Change from baseline in weight at month 3.

    Weight in kilogram measure in clinic at the hospital scales from TANITA or self monitored at home on a Beurer BF 850 scale.

    Time frame: Baseline and month 3.

  4. Change from baseline in weight at month 6.

    Weight in kilogram measure in clinic at the hospital scales from TANITA or self monitored at home on a Beurer BF 850 scale.

    Time frame: Baseline and month 6.

  5. Change from baseline in weight at month 9.

    Weight in kilogram measure in clinic at the hospital scales from TANITA or self monitored at home on a Beurer BF 850 scale.

    Time frame: Baseline and month 9..

  6. Change from baseline in weight at month 12.

    Weight in kilogram measure in clinic at the hospital scales from TANITA or self monitored at home on a Beurer BF 850 scale.

    Time frame: Baseline and month 12.

  7. Change from baseline in weight at month 18.

    Weight in kilogram measure in clinic at the hospital scales from TANITA or self monitored at home on a Beurer BF 850 scale.

    Time frame: Baseline and month 18.

  8. Change from baseline in waist circumference at 6 and 12 month.

    Waist circumference measure in cm with measuring tape.

    Time frame: Baseline and month 6 and 12.

  9. Change from baseline in waist circumference at 6 month.

    Waist circumference measure in cm with measuring tape.

    Time frame: Baseline and month 6.

  10. Change from baseline in blood pressure at12 month.

    Bloodpressure in mm Hg, measured in right arm while sitting down after 5 minits of rest. It will be measured three times and then the mean of the two last measure will be calculated and reported.

    Time frame: Baseline and month 12.

  11. Change from baseline in fasting insulin at 12 month.

    Fasting insulin from blood sample measured in mU/L. Analyzed according to standard routine.

    Time frame: Baseline and month 12.

  12. Change from baseline in fasting glucose at 12 month.

    Fasting glucose from blood sample measured in mmol/L. Analyzed according to standard routine.

    Time frame: Baseline and month 12.

  13. Change from baseline in HbA1c at 12 month.

    HbA1c from blood sample measured in mmol/L. Analyzed according to standard routine.

    Time frame: Baseline and month 12.

  14. Change from baseline in lever enzymes, ASAT, at 12 month.

    ASAT from blood sample measured in µkat/L. Analyzed according to standard routine.

    Time frame: Baseline and month 12.

  15. Change from baseline in lever enzymes, ALAT, at 12 month.

    ALAT from blood sample measured in µkat/L. Analyzed according to standard routine.

    Time frame: Baseline and month 12.

  16. Change from baseline in triglyceride at 12 month.

    Triglyceride from blood sample measured in mmol/L. Analyzed according to standard routine.

    Time frame: Baseline and month 12.

  17. Change from baseline in cholesterol at 12 month.

    Cholesterol from blood sample measured in mmol/L. Analyzed according to standard routine.

    Time frame: Baseline and month 12.

  18. Change from baseline in blood lipid, LDL, at 12 month.

    LDL from blood sample measured in mmol/L. Analyzed according to standard routine.

    Time frame: Baseline and month 12.

  19. Change from baseline in blood lipid, HDL, at 12 month.

    HDL from blood sample measured in mmol/L. Analyzed according to standard routine.

    Time frame: Baseline and month 12.

  20. Change from baseline in food intake according to Riksmaten Flex and 24-hour recalls in 12 month.

    RiksmatenFlex and 24-hour recalls is a validated survey about food habits combined with three 24-hour interviews, where food intake the last 24 h are reported.

    Time frame: Baseline and month 12.

  21. Change from baseline in amount of steps per day according to activity watch at week 52.

    Amount of daily steps will be self-monitored with a sportsbuddy veryfit activity watch and then selfreported in to the study app. The mean of one weeks step will be colected at week 1, 26 and 52.

    Time frame: Baseline (week 1) and 52.

  22. Change from baseline in amount of steps per day according to activity watch at week 26.

    Amount of daily steps will be self-monitored with a sportsbuddy veryfit activity watch and then selfreported in to the study app. The mean of one weeks step will be collected at week 1, 26 and 52.

    Time frame: Baseline (week 1) and week 26.

  23. Change from baseline in health-related quality of life according to PEDS-QL at 12 month

    PEDS-QL is a valid questionaire for evaluating health-related quality of life used by the Swedish childhood obesity treatment register (BORIS). The child will answer if they never, almost never, sometimes, often or always has experience diffrent issues conserning their health.

    Time frame: Baseline and month 12.

  24. Change from baseline in daily well-being on a 10 point VAS-scale at week 26.

    Daily self reported well-being via a VAS-scale from 1-10 (1=worst feeling, 10=best feeling). The mean of one week reported data will be collected at week 1, 26 and 52.

    Time frame: Baseline (week 1), and week 26.

  25. Change from baseline in daily well-being on a 10 point VAS-scale at week 52.

    Daily self reported well-being via a VAS-scale from 1-10 (1=worst feeling, 10=best feeling). The mean of one week reported data will be collected at week 1, 26 and 52.

    Time frame: Baseline (week 1) and 52.

  26. Thoughts on implementation from caregivers after a 12-month digital-physical care.

    Survey about caregivers experience through implementation of digital care. Few easy questions about positive and negative aspects.

    Time frame: At month 12

  27. Thoughts on implementation from patients after a 12-month digital-physical care.

    Survey about patient experience through implementation of digital care. Few easy questions about positive and negative aspects and how they used the app.

    Time frame: At month 12

  28. Semi-structured interviews for a deeper insight in the qualitative aspects concerning digital care.

    Semi-structured interviews with 15-20 of the patient families inte the intervention group. The interview will proceed from open answer questions with the possibility to expand answers.

    Time frame: At month 12.

Other outcomes

  1. Report digital selfmonitored health data.

    Evaluate the precentage of typ 2 diabetes patientens that reported self-monitored health data by the digital communication platform.

    Time frame: At 3 month.

07

Study locations

5 sites
  • Regionalt obesitascentrum
    Gothenburg, Sweden
  • Barnkliniken Halland
    Halmstad, Sweden
  • Barnkliniken Halland
    Kungsbacka, Sweden
  • Överviktenheten Barn
    Malmö, Sweden
  • Barnkliniken Halland
    Varberg, Sweden
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in May 2024, 26 months.

Of 539 non-industry interventional studies with no phase under Pediatric Obesity, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's 26 months is close to that.

Counting every sponsor, half of 541 studies reached it within 25 months; a quarter within 11 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2021
First posted
Feb 21, 2022
StartActual
Mar 9, 2022
Primary completionActual
May 30, 2024
CompletionActual
May 30, 2024
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05247918
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Mar 9, 2022
Primary completion
May 30, 2024
Completion
May 30, 2024
Last update
Mar 17, 2026

Study contacts

Josefin Roswall
study chair · Region Halland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion